Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim for Myeloid Dendritic Cell Deficiency
NCT03063242Phase 2Terminated
- Sponsor
- University of Florida
- Start
- Feb 2017
- Primary completion
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in Myeloid dendritic cell deficiency (mDCD), sponsored by University of Florida. Started Feb 2017; status: terminated.
02
Drugs
sargramostim
03
Conditions
Myeloid dendritic cell deficiency (mDCD)
Beyond the preview
Go deeper on NCT03063242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063242.